News | Image Guided Radiation Therapy (IGRT) | March 30, 2016

Adaptive Image-guided Radiotherapy Effective in Bladder Cancer

Study sees increased bladder preservation rates over surgery with good oncological outcomes

March 30, 2016 — A prospective study examining a trimodality treatment approach in localized bladder cancer cases using adaptive image-guided, intensity-modulated radiation therapy (IG-IMRT) found the bladder preservation rate at three years was 83 percent.

Approximately 150,000 people worldwide die every year as a result of urinary bladder cancer. Patients with moderately advanced bladder cancer typically undergo surgery with removal of the bladder resulting in the use of an external urine bag. The trimodality plan, which consists of the transurethral resection of the bladder tumor (TURBT), IG-IMRT and chemotherapy, was developed as a bladder conservation protocol to preserve bladder function with good oncological outcomes.  

“Adaptive IGRT [with] plan-of-the-day approach for bladder preservation is clinically feasible, with good oncological outcomes and low rates of acute and late toxicities. Dose escalation is safe and possibly improves outcomes in bladder preservation,” said Vedang Murthy, M.D., radiation oncology, Tata Memorial Centre, Mumbai, India, and lead author of the study.

The study, “Clinical Outcomes With Dose-Escalated Adaptive Radiation Therapy for Urinary Bladder Cancer: A Prospective Study,” was published in the International Journal of Radiation Oncology • Biology • Physics (Red Journal).

“With adaptive IGRT, increasing the dose becomes possible, and serious side effects may be kept low, ensuring a good quality of life for our patients,” Murthy said.

The study looked at 44 patients between August 2008 and August 2014. Thirty-nine (88 percent) patients were male and five (11 percent) were female, ranging in ages from 55 to 72. Eighty-eight percent of patients had stage 2 disease. Patients underwent maximal safe resection of bladder tumor and concurrent platinum-based chemotherapy, and those with large tumors were offered induction chemotherapy.

RT planning was done using either three (n=34) or six (n=10) non-concentrically grown planning target volumes (PTV). Patients received 64 Gy in 32 fractions to the whole bladder and 55 Gy to the pelvic nodes. If appropriate, they received a simultaneous integrated boost to the tumor bed to 68 Gy. Daily megavoltage imaging was used to find the most appropriate PTV encompassing bladder for the particular day with the plan-of-the-day approach.

At six to ten weeks post-treatment, all patients had a complete response. The study had a median follow-up of 30 months. Overall survival at the last follow-up was 77 percent (34 patients). Among those who died, three died from comorbidities and were disease-free at the time of death.

The three-year locoregional control (LRC), disease-free survival and overall survival (OS) rates were 78 percent, 66 percent and 67 percent, respectively. Rates of LRC and OS were better in patients who received dose escalation. Acute and late Radiation Therapy Oncology Group (RTOG) grade 3 genitourinary toxicity was seen in five (11 percent) and two (four percent) patients, respectively. No acute or late RTOG grade 3 or higher gastrointestinal toxicity occurred.

“Adaptive RT (ART) further helps in reduction of doses to normal tissues and improves accuracy of delivery,” Murthy said. “These procedures, in theory, should result in less acute and late toxicity, while allowing for dose escalation to gross tumor to improve outcomes.”

“Although a number of investigators have conceived and developed a variety of ART techniques, there are few clinical outcome data to validate this dosimetric concept. The present proof-of-concept prospective study was conducted with the aim of establishing the safety, efficacy and feasibility of IG-IMRT-based ART in clinical practice,” he said.

More follow-up with larger groups of patients is needed to establish the novel technique as the standard, Murthy said, but results from the study have shown the possibilities of ART in bladder cancer patients.

“These results provide proof of concept of using adaptive IGRT in the clinic,” Murthy said. “This will hopefully lead to more and more suitable patients undergoing bladder preservation around the world.”

For more information: www.redjournal.org

Related Content

AAPM 2019 Features More Than 40 Presentations on ViewRay's MRIdian MRI-guided Radiotherapy
News | Image Guided Radiation Therapy (IGRT) | July 16, 2019
ViewRay Inc. announced that the company's MRIdian System is the focus of more than 40 abstracts selected by the...
RaySearch Releases Version 3A of RayCare Oncology Information System
Technology | Oncology Information Management Systems (OIMS) | July 15, 2019
RaySearch has released RayCare 3A, a new version of the next-generation oncology information system (OIS). RayCare is...
IBA Launches Monte Carlo Patient QA for Varian Halcyon at AAPM 2019
Technology | Quality Assurance (QA) | July 10, 2019
IBA announced the launch of the latest functionality of the SciMoCa Monte Carlo Patient QA solution at the 61st annual...
Researchers Use Artificial Intelligence to Deliver Personalized Radiation Therapy
News | Radiation Therapy | July 09, 2019
New Cleveland Clinic-led research shows that artificial intelligence (AI) can use medical scans and health records to...
The Beamscan 3-D water phantom with the Varian Halcyon radiotherapy system

The Beamscan 3-D water phantom with the Varian Halcyon radiotherapy system. Image courtesy of PTW.

News | Quality Assurance (QA) | July 08, 2019
At this year’s American Association of Physicists in Medicine (AAPM) show, July 14-18 in San Antonio, Texas, PTW will...
Aktina Medical Partners With Elekta for Global Distribution of Interlocking SRS Cones
News | Radiation Therapy | July 05, 2019
Aktina Medical announced that Elekta Instrument AB, based in Sweden, will offer and distribute the Aktina line of...
Delta T1 Maps Provide Quantitative, Automated Solution to Assess Brain Tumor Burden
News | Neuro Imaging | July 05, 2019
Imaging Biometrics LLC (IB) a subsidiary of IQ-AI Ltd., is highlighting a recently published study in the American...
Civco Displaying Universal Couchtop ProForm Head & Neck Solution at AAPM
News | Patient Positioning Radiation Therapy | July 03, 2019
The upcoming release of Civco’s Universal Couchtop ProForm Head & Neck Solution will allow proton therapy centers...
RaySearch Releases Version 9A of RayStation Treatment Planning System
Technology | Treatment Planning | July 02, 2019
RaySearch announced the release of RayStation 9A, the latest version of its radiation therapy treatment planning system...